

## **MEETING ABSTRACT**



# Peripherally induced Foxp3<sup>+</sup> regulatory T cells mediates the immunomodulatory effect of intravenous immunoglobulin in an experimental model of allergic airway disease

Amir H Massoud<sup>1,3\*</sup>, Gabriel Kaufman<sup>1</sup>, Madelaine Taylor<sup>1</sup>, Marianne Beland<sup>1</sup>, Ciriaco A Piccirillo<sup>2</sup>, Walid M Mourad<sup>3</sup>, Bruce D Mazer<sup>1</sup>

*From* Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting 2013 Toronto, Canada. 3-6 October 2013

### Background

IVIg is a polyclonal IgG preparation with potent immune-modulating properties. We demonstrated that IVIg protects against airway hyperreactivity (AHR) and airway inflammation in mouse models of allergic airway disease, accompanied by peripheral induction of Foxp3 <sup>+</sup>regulatory T-cells (iT<sub>reg</sub>). The requirement of IVIg-induced iT<sub>reg</sub> and their antigen-specificity in attenuation of AHR and airway inflammation remains unknown.

### Methods

We utilized DEREG mice, carrying a transgenic diphtheria toxin receptor under the control of the Foxp3 promoter, allowing for selective depletion of  $Foxp3^+T_{reg}$  by the application of diphtheria toxin (DT). Mice were sensitized and challenged with ovalbumin (OVA) and treated with IVIg. AHR was measured using a FlexiVent small animal ventilator. Total and antigen-specific IgE, as well as pro-inflammatory cytokines levels were determined in serum and alveolar lavage, using ELISA.

### Results

In the absence of Treg, due to multiple DT doses before and after the treatment, IVIg was not able to attenuate AHR, diminish IgE levels and Th-2 type cytokine production, nor alleviate airway inflammation. However, mice in which the pre-established  $T_{reg}$  cells (n $T_{reg}$ ) were depleted before but not following IVIg treatment demonstrated an

\* Correspondence: amir.hossein.massoud@umontreal.ca

<sup>1</sup>McGill University, Dept. of Experimental Medicine, Montreal, QC, Canada, H2X 2P2

Full list of author information is available at the end of the article



#### Conclusions

 $T_{\rm reg}$  can be induced from effector CD4<sup>+</sup>T-cells in the absence of  $nT_{\rm reg}$ . IVIg-induced antigen specific  $T_{\rm reg}$  are capable of suppressing all aspects of antigen-driven airway inflammation in an antigen-specific manner.

#### Authors' details

<sup>1</sup>McGill University, Dept. of Experimental Medicine, Montreal, QC, Canada, H2X 2P2. <sup>2</sup>McGill University Dept. of Microbiology and Immunology, Montreal, QC, Canada, H3G 1A4. <sup>3</sup>Universite de Montral, Dept. Microbiologie et Immunologie Montreal, QC, Canada, H2X 3J4.

Published: 3 March 2014

doi:10.1186/1710-1492-10-S1-A50

**Cite this article as:** Massoud *et al.*: **Peripherally induced Foxp3**<sup>+</sup> regulatory T cells mediates the immunomodulatory effect of intravenous immunoglobulin in an experimental model of allergic airway disease. *Allergy, Asthma & Clinical Immunology* 2014 **10**(Suppl 1):A50.



© 2014 Massoud et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.